[go: up one dir, main page]

CY1107422T1 - Φουραζανοβενζιμιδαζoλες - Google Patents

Φουραζανοβενζιμιδαζoλες

Info

Publication number
CY1107422T1
CY1107422T1 CY20081100454T CY081100454T CY1107422T1 CY 1107422 T1 CY1107422 T1 CY 1107422T1 CY 20081100454 T CY20081100454 T CY 20081100454T CY 081100454 T CY081100454 T CY 081100454T CY 1107422 T1 CY1107422 T1 CY 1107422T1
Authority
CY
Cyprus
Prior art keywords
compounds
formula
carbonyl group
neoplastic
treatment
Prior art date
Application number
CY20081100454T
Other languages
English (en)
Inventor
Martin Eberle
Felix Bachmann
Alessandro Strebel
Subho Roy
Sudhir Srivastava
Goutam Saha
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of CY1107422T1 publication Critical patent/CY1107422T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)

Abstract

Η εφεύρεση αναφέρεται σε ενώσεις του τύπου (I) στον οποίο R αντιπροσωπεύει αρύλιο ή έτεροαρύλιο, Χ αντιπροσωπεύει οξυγόνο, μία καρβονυλομάδα, ένα παράγωγο οξίμης μίας καρβονυλομάδας ή μία α,β-ακόρεστη καρβονυλομάδα, και οι υποκατάστατες R1 έως R6 έχουν τις σημασίες που δίνονται στην περιγραφή, για χρήση ως φάρμακα. Η εφεύρεση αναφέρεται σε νέες ενώσεις του τύπου (I), σε μεθόδους για την σύνθεση τέτοιων ενώσεων, σε φαρμακευτικές συνθέσεις που περιέχουν ενώσεις του τύπου (I), στην χρήση μίας ένωσης του τύπου (I) για την παρασκευή μίας φαρμακευτικής σύνθεσης για την θεραπευτική αγωγή νεοπλασματικών και αυτοάνοσων ασθενειών, και σε μεθόδους θεραπευτικής αγωγής νεοπλασματικών και αυτοάνοσων ασθενειών με χρήση τέτοιων ενώσεων του τύπου (I) ή φαρμακευτικών συνθέσεων που τις περιέχουν.
CY20081100454T 2003-05-23 2008-04-23 Φουραζανοβενζιμιδαζoλες CY1107422T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03405365 2003-05-23
EP04733874A EP1636215B1 (en) 2003-05-23 2004-05-19 Furazanobenzimidazoles

Publications (1)

Publication Number Publication Date
CY1107422T1 true CY1107422T1 (el) 2012-12-19

Family

ID=33462273

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100454T CY1107422T1 (el) 2003-05-23 2008-04-23 Φουραζανοβενζιμιδαζoλες

Country Status (14)

Country Link
US (2) US7385061B2 (el)
EP (1) EP1636215B1 (el)
JP (2) JP4829791B2 (el)
CN (1) CN100434428C (el)
AT (1) ATE384718T1 (el)
CA (1) CA2526026C (el)
CY (1) CY1107422T1 (el)
DE (1) DE602004011515T2 (el)
DK (1) DK1636215T3 (el)
ES (1) ES2300775T3 (el)
PL (1) PL1636215T3 (el)
PT (1) PT1636215E (el)
SI (1) SI1636215T1 (el)
WO (1) WO2004103994A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
DK1723138T3 (da) * 2004-02-11 2010-08-23 Basilea Pharmaceutica Ag Substituerede benzimidazoler og deres anvendelse til at inducere apoptose
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
DK2459553T3 (da) * 2009-07-27 2014-11-03 Basilea Pharmaceutica Ag Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme
PL2666014T3 (pl) * 2011-01-21 2017-07-31 Basilea Pharmaceutica Ag Zastosowanie glu-tubuliny jako biomarkera odpowiedzi na furazanobenzoimidazole
PL2666016T3 (pl) 2011-01-21 2017-07-31 Basilea Pharmaceutica Ag Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej
JP6302674B2 (ja) * 2011-01-21 2018-03-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用
CA2824497A1 (en) * 2011-02-24 2012-08-30 Basilea Pharmaceutica Ag Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
AU2012234297B2 (en) 2011-03-29 2016-03-03 Basilea Pharmaceutica Ag Use of phospho-Akt as a biomarker of drug response
AU2016341399B2 (en) * 2015-10-22 2022-11-24 Basilea Pharmaceutica International AG Use of EB1 as a biomarker of drug response
CA3058695A1 (en) 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
CA3061429A1 (en) 2017-05-05 2018-11-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2020058405A1 (en) 2018-09-20 2020-03-26 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US20220370418A1 (en) * 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CN111454254B (zh) 2020-04-26 2023-06-02 云白药征武科技(上海)有限公司 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用
CN111423429A (zh) * 2020-05-19 2020-07-17 江西科技师范大学 苯并咪唑联呋咱类系列化合物及其合成方法
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
DE3100771A1 (de) 1981-01-13 1982-08-26 USV Pharmaceutical Corp., Tuckahoe, N.Y. Heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE4307105A1 (de) * 1993-03-06 1994-09-08 Cassella Ag Hydroxymethylfurazancarbonsäurederivate
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic

Also Published As

Publication number Publication date
PT1636215E (pt) 2008-04-29
ATE384718T1 (de) 2008-02-15
EP1636215A1 (en) 2006-03-22
CN100434428C (zh) 2008-11-19
JP5670266B2 (ja) 2015-02-18
PL1636215T3 (pl) 2008-09-30
USRE42890E1 (en) 2011-11-01
CA2526026C (en) 2012-03-20
CN1812986A (zh) 2006-08-02
JP2006528238A (ja) 2006-12-14
WO2004103994A1 (en) 2004-12-02
JP2011207909A (ja) 2011-10-20
DE602004011515T2 (de) 2009-01-29
CA2526026A1 (en) 2004-12-02
US20070043061A1 (en) 2007-02-22
JP4829791B2 (ja) 2011-12-07
SI1636215T1 (sl) 2008-06-30
DE602004011515D1 (de) 2008-03-13
ES2300775T3 (es) 2008-06-16
US7385061B2 (en) 2008-06-10
DK1636215T3 (da) 2008-06-02
EP1636215B1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
CY1107422T1 (el) Φουραζανοβενζιμιδαζoλες
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
SE0202133D0 (sv) Novel compounds
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
SE0300119D0 (sv) Novel compounds
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
SE0302116D0 (sv) Novel compounds
HK1082250A1 (en) Thiophene carboxamides as inhibitors of the enzymeikk-2
SE0302139D0 (sv) Novel compounds
ATE482933T1 (de) Sulfopyrrolderivate
ATE381554T1 (de) Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
SE0300092D0 (sv) Novel compounds
SE0402925D0 (sv) Novel Compounds
MXPA05010020A (es) Derivados de oxamida.
SE0300456D0 (sv) Novel compounds
DE602005022284D1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
SE0401763D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
TW200616636A (en) Novel compounds
SE0303090D0 (sv) Novel compounds
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
SE0302755D0 (sv) Novel compounds
ATE485822T1 (de) Phenylaminopyridine und phenylaminopyrazine